[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-362958-105":59,"doc-detail-362958-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","cis-regulatory-and-long-noncoding-rna-alterations-in-breast-cancer-current-insights-biomarker-utility-and-the-critical-need-for-functional-validation","Cis-regulatory and long noncoding RNA alterations in breast cancer - current insights, biomarker utility, and the critical need for functional validation","","Breast cancer’s global prevalence drives demand for novel biomarkers that can guide therapy and improve patient outcomes. This Review synthesizes current evidence on cis-regulatory alterations in promoters and enhancers and on long noncoding RNAs (lncRNAs), linking promoter and enhancer mutations and specific lncRNAs (e.g., HOTAIR) to progression, metastasis, and poor survival. By integrating preclinical and clinical findings, it highlights biomarker and therapeutic promise while stressing the need for more specific functional validation to clarify mechanisms and enable refined prognostic and predictive strategies.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/cis-regulatory-and-long-noncoding-rna-alterations-in-breast-cancer-current-insights-biomarker-utility-and-the-critical-need-for-functional-validation/362958/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/cis-regulatory-and-long-noncoding-rna-alterations-in-breast-cancer-current-insights-biomarker-utility-and-the-critical-need-for-functional-validation/362958.png","ImageObject",300,407,{"name":92,"@type":93},"Aditya","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-20","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is studying the noncoding genome important in breast cancer?","Question",{"text":112,"@type":113},"Because most of the genome is involved in regulating gene expression and noncoding-region mutations are linked to cancer risk, progression, and treatment response.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which types of cis-regulatory alterations are discussed?",{"text":117,"@type":113},"The Review focuses on mutations in cis-regulatory regions, specifically promoters and enhancers, and explains their associations with breast cancer outcomes.",{"name":119,"@type":110,"acceptedAnswer":120},"What is the role of long noncoding RNAs in the article?",{"text":121,"@type":113},"It compiles evidence for lncRNAs such as HOTAIR and links them to progression, metastasis, and poor survival while considering biomarker and therapeutic potential.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},362958,1790363346,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962085564549,"https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","Cis-regulatory and long noncoding RNA alterations in breast cancer – current insights, biomarker utility, and the critical need for functional validation  \nArnau Cuy Saqus 1 , Aracele Martinez-Mendez 1, John Crown2 and Alex Eustace 1,3  \n1 Life Science Institute, Dublin City University, Ireland  \n2 Medical Oncology Department, St Vincent’s University Hospital, Dublin, Ireland  \n3 School of Biotechnology, Dublin City University, Ireland  \nKeywords  \nbiomarker discovery; breast cancer;  \nenhancer mutations; long-noncoding RNAs; noncoding genome; promoter mutations  \nCorrespondence  \nA. Cuy Saqus, Life Science Institute, DCU Glasnevin Campus, Collins Avenue Extension, D09 NR58, Dublin, Ireland  \nTel: +34646527807  \nE-mail: [arnaucuy.saques@dcu.ie](arnaucuy.saques@dcu.ie)  \n(Received 1 July 2025, revised 5 September 2025, accepted 5 October 2025, available online 13 November 2025)  \ndoi:10 . 1002/1878-0261 .70157  \nBreast cancer’s global prevalence underscores a critical need for novel biomarkers to guide treatment and improve patient outcomes. Biomarker discovery historically focused on mutations in protein coding regions, comprising merely 1% of the genome. However, with advances in whole-genome sequencing, the functional signiﬁcance of the noncoding genome—comprising the remaining 99%—has become increasingly evident. Noncoding regions play a vital role in regulating gene expression, and mutations within these regions have been associated with cancer risk, progression, and treatment response. This Review compiles and synthesizes current knowledge on cis-regulatory alterations (promoters/enhancers) and long noncoding RNAs (lncRNAs) in breast cancer. Key examples include promoter mutations [e.g., rs2279744 (Mouse double minute 2 homolog gene; MDM2)], enhancer mutations [e.g., rs4784227 (thymocyte selection-associated high mobility group box family member 3 gene; TOX3)], and lncRNAs [e.g., HOX transcript antisense intergenic RNA (HOTAIR)] linked to progression, metastasis, and poor survival. Integrating preclinical (in vitro, in vivo) and clinical ﬁndings, we emphasize the biomarker and therapeutic potential of these noncoding alterations. This Review also critically identiﬁes the pressing need for more speciﬁc functional validation studies to fully elucidate their mechanistic roles. This emerging ﬁeld offers promising opportunities to advance personalized medicine and reﬁne prognostic/predictive strategies for breast cancer patients.  \nAbbreviations  \nBC, breast cancer; BRCA1, breast cancer gene 1; CBP, CREB-binding protein; CREs, Cis-regulatory elements; CTCF, CCCTC-binding factor; DANCR, differentiation antagonizing non-protein coding RNA; ER, estrogen receptor; ESR1, estrogen receptor 1 gene; ESR2, estrogen receptor 2; ETS, E-twenty-six; FNTB, farnesyltransferase subunit b; FOXA1, forkhead box protein A1; H19, lncRNA H19; HER2, human epidermal growth factor receptor 2; HOTAIR, HOX transcript antisense intergenic RNA; lncRNA, long noncoding RNAs; MALAT1, metastasis associated lung adenocarcinoma transcript 1; MDM2, mouse double minute 2 homolog; NEAT1, nuclear paraspeckle assembly transcript 1; OAS1, 20-50-oligoadenylate synthetase 1; RMRP, RNA component of mitochondrial RNA processing endoribonuclease; SNPs, single nucleotide polymorphisms; TERT, telomerase reverse transcriptase; TINCR, tissue differentiation-inducing non-protein coding RNA; TNBC, triple negative breast cancer; TNFSF10, tumor necrosis factor superfamily member 10; TOX3, thymocyte selection associated with high mobility group box family member 3; TRAIL, tumor necrosis factor-related apoptosis-inducing ligand; WGS, whole-genome sequencing.  \nMolecular Oncology 20 (2026) 877–893 ª 2025 The Author(s) . Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.  \nThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medi","cbCairWbT6ywrl3U","https://ap.wps.com/l/cbCairWbT6ywrl3U","pdf",2219488,17,"English","# Introduction: The emerging significance of the noncoding genome in breast cancer\n## Study of the noncoding genome","[{\"question\":\"Why is studying the noncoding genome important in breast cancer?\",\"answer\":\"Because most of the genome is involved in regulating gene expression and noncoding-region mutations are linked to cancer risk, progression, and treatment response.\"},{\"question\":\"Which types of cis-regulatory alterations are discussed?\",\"answer\":\"The Review focuses on mutations in cis-regulatory regions, specifically promoters and enhancers, and explains their associations with breast cancer outcomes.\"},{\"question\":\"What is the role of long noncoding RNAs in the article?\",\"answer\":\"It compiles evidence for lncRNAs such as HOTAIR and links them to progression, metastasis, and poor survival while considering biomarker and therapeutic potential.\"}]","Cis-regulatory and long noncoding RNA alterations in breast cancer - current insights, biomarker utility, and the critical need for functional validation | PDF",1790149543,43,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/794cb975d14ffde954a3e60fe35cf18a.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a657fbdfab6cd5a22980cb72ed557286.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/90d583b2780968e17ee85df2d4c6a57f.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7b89e7d08a166abbd170912aa5797943.webp",980,1287]